

CASE CT2662DIV2

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Janet Sudol
Type or print name

Janet Sudol
Signature

April 27, 2004
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

VRUDHULA ET AL.

APPLICATION NO: 10/771,766

FILED: 2/4/04

FOR: IMIDAZOLYL DERIVATIVES AS CORTICOTROPIN RELEASING FACTOR INHIBITORS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the filing date of the application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.


In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Some of the listed references are of record in parent Application No. 10/044,183 filed January 11, 2002, and copies are available therein. However, applicants are willing to send copies of any or all of these references at the Examiner's request.

Some of the listed references were cited in a search report in a corresponding European application. Copies of these references and the search report are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,


Shah R. Makujina
Attorney for Applicants
Reg. No. 41,174

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(203) 677-7268

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
CT2662DIV2
APPLICATION NO.
10/771,766
APPLICANT
VRUDHULA ET AL.
FILING DATE
FEBRUARY 4, 2004

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
	AG	EP 0 812 831 A1	17 Dec 97	EP				
	AH	EP 0 778 277 A1	11 Jun 97	EP				
	AI	WO 98/35967	20 Aug 98	PCT				
	AJ	WO 99/01454	14 Jan 99	PCT				
	AK	WO 99/10350	04 Mar 99	PCT				
	AL	WO 99/67247	29 Dec 99	PCT				
	AM	WO 00/01675	13 Jan 00	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AN	WO 00/01697	13 Jan 00	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AO	WO 00/39127	06 Jul 00	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AP	WO 00/59907	12 Oct 00	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AQ	WO 00/59908	12 Oct 00	PCT			<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	DUNN, et al., "Physiological and behavioral response to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses?", Brain Research Reviews, 15, 1990, pp. 71-100
	AS	GULYAS, et al., "Potent, structurally constrained agonists and competitive antagonists of corticotropin-releasing factor," Prac. Natl. Acad. Sci. USA, 92, 1995, pp. 10575-10579
	AT	McCARTHY, et al., "Recent Advances with the CRF1 Receptor: Design of Small Molecule Inhibitors, Receptor Subtypes and Clinical Indications," Current Pharmaceutical Design, 5, 1999, pp. 289-315

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
CT2662DIV2
APPLICATION NO.
10/771,766
APPLICANT
VRUDHULA ET AL.
FILING DATE
FEBRUARY 4, 2004

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AA	HOLSBOER, "The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety," Journal of Psychiatric Research, 33, 1999, pp. 181-214
AB	BANKI, et al., "CSF corticotropin-releasing hormone and somatostatin in major depression: response to antidepressant treatment and relapse," European Neuropsychopharmacology, 2, 1992, pp. 107-113
AC	ZOBEL, et al., "Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression, the first 20 patients treated," Journal of Psychiatric Research, 34, 2000, pp. 171-181
AD	WEBSTER, et al., "Corticotropin-Releasing Hormone and Inflammation," Annals New York Academy of Sciences, 840, 1998, pp. 21-62
AE	GILLIGAN, et al., "Corticotropin Releasing Factor (CRF) Receptor Modulators: Progress and Opportunities for New Therapeutic Agents," Journal of Medicinal Chemistry, 43, 9, 2000, pp. 1641-1660
AF	McCARTHY, et al., "Chapter 2. Recent Progress in Corticotropin-Releasing Factor Receptor Agents," Annual Reports in Medicinal Chemistry, 34, 1999, pp. 11-20
AG	
AH	
AI	
AJ	
AK	
AL	
AM	
AN	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
CT2662DIV2
APPLICATION NO.
10/771,766
APPLICANT
VRUDHULA ET AL.
FILING DATE
FEBRUARY 4, 2004

Group

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLAS S	TRANSLATION	
							YES	NO
	AA	EP 0 902 029 A1	17 Mar 99	EPO			<input type="checkbox"/>	<input type="checkbox"/>
	AB	WO 01/007440 A	01 Feb 01	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AC	EP 0 970 958 A	12 Jan 00	EPO			<input type="checkbox"/>	<input type="checkbox"/>
	AD	WO 97/29109 A	14 Aug 97	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AE						<input type="checkbox"/>	<input type="checkbox"/>
	AF						<input type="checkbox"/>	<input type="checkbox"/>
	AG						<input type="checkbox"/>	<input type="checkbox"/>
	AH						<input type="checkbox"/>	<input type="checkbox"/>
	AI						<input type="checkbox"/>	<input type="checkbox"/>
	AJ						<input type="checkbox"/>	<input type="checkbox"/>
	AK						<input type="checkbox"/>	<input type="checkbox"/>
	AL						<input type="checkbox"/>	<input type="checkbox"/>
	AM						<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>
	AR						<input type="checkbox"/>	<input type="checkbox"/>
	AS						<input type="checkbox"/>	<input type="checkbox"/>
	AT						<input type="checkbox"/>	<input type="checkbox"/>
	AU						<input type="checkbox"/>	<input type="checkbox"/>
	AV						<input type="checkbox"/>	<input type="checkbox"/>
	AW						<input type="checkbox"/>	<input type="checkbox"/>
	AX						<input type="checkbox"/>	<input type="checkbox"/>
	AY						<input type="checkbox"/>	<input type="checkbox"/>
	AZ						<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.